ସିଟାଗ୍ଲିପଟିନ

ସିଟାଗ୍ଲିପଟିନ
Clinical data
Pronunciation	/sɪtəˈɡlɪptɪn/ (listen)
Trade names	Januvia, Tesavel, Xelevia, others
AHFS/Drugs.com	monograph
MedlinePlus	a606023
data	EU EMA: yes; US DailyMed: Sitagliptin;
Pregnancy; category	AU: B3 ; US: B (No risk in non-human studies) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	87%
Protein binding	38%
Metabolism	Liver (CYP3A4- and CYP2C8-mediated)
Elimination half-life	8 to 14 h
Excretion	Kidney (80%)
Identifiers
	IUPAC name (R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine;
ECHA InfoCard	100.217.948
Chemical and physical data
Formula	C16H15F6N5O
Molar mass	୪୦୭.୩୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1cc(c(F)cc1F)C[C@@H](N)CC(=O)N3Cc2nnc(n2CC3)C(F)(F)F;
	InChI InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 ; Key:MFFMDFFZMYYVKS-SECBINFHSA-N ;
(verify)

ସିଟାଗ୍ଲିପଟିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଜାନୁଭିଆ, ଏକ ଔଷଧ ଯାହା ମଧୁମେହ ପ୍ରକାର 2ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୨] ଯୁକ୍ତରାଜ୍ୟରେ ଏହା ମେଟଫର୍ମିନ୍ କିମ୍ବା ସଲଫୋନିଲୁରିଆ ଅପେକ୍ଷା କମ୍ ପସନ୍ଦ କରାଯାଏ | ^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୪] ଏହା ଏକ ମିଶ୍ରତ ବଟିକା ଯେପରିକି ମେଟଫର୍ମିନ୍ / ସାଇଟାଗ୍ଲିପଟିନ୍ ଭାବରେ ମଧ୍ୟ ଉପଲବ୍ଧ ଅଛି | ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡବିନ୍ଧା, ଗୋଡ ଫୁଲା ଏବଂ ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ ହୋଇପାରେ | ^[୨] ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଞ୍ଜିଓଇଡିମା, ନିମ୍ନ ରକ୍ତ ଶର୍କରା, ବୃକ୍‌କ ସମସ୍ୟା, ଅଗ୍ନାଶୟ ପ୍ରଦାହ ଓ ଗଣ୍ଠି ଯନ୍ତ୍ରଣା ହୋଇପାରେ | ^[୪] ଗର୍ଭାବସ୍ଥାରେ କିମ୍ବା ସ୍ତନ୍ୟପାନ କରାଇବା ନିରାପଦ କି ନୁହେଁ ତାହା ଅସ୍ପଷ୍ଟ ରହିଛି। ^[୫] ଏହା ଡାଇପେପ୍ଟିଡିଲ-୪ (ଡିପିପି-୪) ଇନହିବିଟର ଶ୍ରେଣୀର ଏକ ଔଷଧ ଯାହା ଇନସୁଲିନ ଉତ୍ପାଦନ ବୃଦ୍ଧି ଏବଂ ଅଗ୍ନାଶୟରୁ ଗ୍ଲୁକାଗନ ଉତ୍ପାଦନ ହ୍ରାସ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୋଇଥାଏ | ^[୪]

ମର୍କ ଆଣ୍ଡ କମ୍ପାନୀ ଏହି ସିଟାଗ୍ଲିପଟିନ ଔଷଧ ବିକଶିତ କରିଛନ୍ତି ଯାହା ୨୦୦୬ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ଏହି ଔଷଧର ଯୁକ୍ତରାଜ୍ୟରେ ଏକ ମାସର ଯୋଗାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୩୩.୨୬ ପାଉଣ୍ଡ ।^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ଔଷଧ ମୂଲ୍ୟ ପ୍ରାୟ ୪୦୫.୦୦ ଡଲାର | ^[୬] ୨୦୧୭ରେ, ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୯୫ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଆଠ ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା |^[୭] ^[୮]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ Herman GA, Stevens C, van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA (December 2005). "Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses". Clin Pharmacol Ther. 78 (6): 675–88. doi:10.1016/j.clpt.2005.09.002. PMID 16338283.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Sitagliptin Phosphate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
↑ ^୩.୦ ^୩.୧ BNF (80 ed.). London: BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. pp. 734–734. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Sitagliptin Phosphate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
↑ "Sitagliptin Pregnancy and Breastfeeding Warnings". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 6 March 2019. Retrieved 3 March 2019.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
↑ "Sitagliptin Phosphate - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.

[Herman-1] ୧.୦ ^୧.୧ Herman GA, Stevens C, van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA (December 2005). "Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses". Clin Pharmacol Ther. 78 (6): 675–88. doi:10.1016/j.clpt.2005.09.002. PMID 16338283.

[AHFS2019-2] ୨.୦ ^୨.୧ ^୨.୨ "Sitagliptin Phosphate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.

[BNF80-3] ୩.୦ ^୩.୧ BNF (80 ed.). London: BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. pp. 734–734. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[autogen1-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ "Sitagliptin Phosphate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.

[Preg2019-5] "Sitagliptin Pregnancy and Breastfeeding Warnings". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 6 March 2019. Retrieved 3 March 2019.

[NADAC2019-6] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-7] "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.

[ref1-8] "Sitagliptin Phosphate - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]